ET80 Stock Chart & Stats
€4.44
€0.20(4.34%)
At close: 4:00 PM EDT
€4.44
€0.20(4.34%)
Day’s Range― - ―
52-Week Range€1.49 - €7.89
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€5.64M
Enterprise Value€1.56M
Total Cash (Recent Filing)€5.27M
Total Debt (Recent Filing)€1.95M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.03
Shares Outstanding996,394
10 Day Avg. Volume1
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue TrendThe return to modest revenue growth suggests some stabilization in demand and commercial execution after the prior decline. If maintained, a firmer top line could provide operating leverage, support investment in the pipeline, and create a foundation for future earnings improvement.
Improving Margins And Narrower LossesHigher gross margin and materially narrower losses indicate progress in the company’s operating economics, even though profitability remains negative. Sustaining these improvements would reduce the path to breakeven and make future revenue growth more valuable through stronger incremental contribution.
Conservative Capital StructureLow leverage gives COSCIENS greater financial flexibility than a highly indebted company and reduces the immediate burden of interest and refinancing obligations. This balance-sheet position can help preserve strategic options while management works to improve profitability and cash generation.
Bears Say
Persistent UnprofitabilityThe company remains deeply unprofitable despite the reduction in absolute losses, so its business model has not yet demonstrated sustainable earnings power. Continued negative margins can constrain reinvestment, limit internal funding, and keep results dependent on further operating improvement.
Continued Cash BurnNegative operating and free cash flow show that current operations are consuming rather than producing cash. Although outflows improved from earlier periods, persistent burn can erode financial flexibility and increase the importance of achieving breakeven before funding requirements become more pressing.
Weak Shareholder ReturnsA deeply negative return on equity indicates that the capital invested in the company is not currently generating economic returns for shareholders. Unless losses narrow substantially and operating performance improves, this weak return profile can remain a durable constraint on capital efficiency.
COSCIENS Biopharma News
ET80 FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was €1.49 and its highest was €7.89 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is €5.64M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Nov 17, 2026 which is in 22 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -€0.17 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -€0.17 in its last earnings report. Following the earnings report the stock price went up 5.329%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in DE:ET80
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―